R-801
Pre-clinical- Indications
- Glaucoma
Company intelligence / Profile preview
Radikal Therapeutics
Vineyard Haven / West Tisbury / Beverly, Massachusetts, United Stateslinkedin.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Radikal Therapeutics has several programs in preclinical development targeting oxidative stress and ion channel modulation for kidney disease and glaucoma. One program targeting CXCR3 for type 1 diabetes was discontinued. No clinical results have been published as of June 2025.
- Therapeutic areas
- GastroenterologyEndocrinologyOphthalmologyNephrology
- Modalities
- Small moleculeSynthetic peptide
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Radikal Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Radikal Therapeutics.